Insilico Medicines Reports 40% ORR at 130mg for Generic AI-Designed Pan-TEAD Inhibitor ISM6331 in Pretreated Mesothelioma at ESMO 2026. Company announcement - FT.com.

Financial Times Markets · 26 Oct, 13:00 UTC · Source

More on Radar

Want to see every report in real time?

Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.